Jounce Therapeutics Inc JNCE:NASDAQ

Last Price$3.03NASDAQ Previous Close - Last Trade as of 4:00PM ET 6/30/22

Today's Change-0.01(0.33%)
Bid (Size)$2.50 (2)
Ask (Size)$3.80 (5)
Day Low / High$2.87 - 3.11
Volume289.7 K
  • Latest Stories
  • Commentary and Analysis
Piper Sandler Lowers Jounce Therapeutics' Price Target to $9 From $17, Maintains Overweight Rating
9:56AM ET 5/23/2022 MT Newswires

Jounce Therapeutics (JNCE) has an average rating of outperform and price targets ranging from $7 to $20, according to analysts polled by Capital IQ. (MT...

Jounce Therapeutics' Shares Drop After Baird Downgrade
2:10PM ET 5/11/2022 MT Newswires

Shares of Jounce Therapeutics (JNCE) were down almost 19% in Wednesday afternoon trading after Baird downgraded the clinical-stage drugmaker's stock to...

--Baird Downgrades Jounce Therapeutics to Neutral From Outperform, Adjusts Price Target to $7 From $15
7:23AM ET 5/11/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--Raymond James Upgrades Jounce Therapeutics to Strong Buy From Outperform, Adjusts Price Target to $20 From $15
8:02AM ET 5/06/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

SMBC Nikko Starts Jounce Therapeutics at Outperform With $17 Price Target
4:52AM ET 3/16/2022 MT Newswires

Jounce Therapeutics (JNCE) has an average rating of outperform and price targets ranging from $15 to $17, according to analysts polled by Capital IQ. (MT...

Cowen Upgrades Jounce Therapeutics to Outperform From Market Perform
7:24AM ET 2/04/2022 MT Newswires

Jounce Therapeutics (JNCE) has an average rating of outperform and price targets ranging from $15 to $17, according to analysts polled by Capital IQ. (MT...

Top Premarket Decliners
8:09AM ET 12/20/2021 MT Newswires

Jounce Therapeutics (JNCE) shares fell 33% following Friday's 7% gain. Tenax Therapeutics (TENX) shares declined 28%, erasing Friday's 4.6% increase....

--Raymond James Adjusts Price Target on Jounce Therapeutics to $15 from $10, Keeps Outperform Rating
12:39PM ET 11/05/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Jounce Therapeutics Q3 Per-Share Net Loss Narrows
11:48AM ET 11/04/2021 MT Newswires

Jounce Therapeutics (JNCE) on Thursday reported Q3 diluted net loss of $0.59 per share, narrower $0.73 a year earlier. The pharmaceutical company said its...

Jounce Therapeutics Initiates Enrollment of Phase 1 Trial Cohorts of JTX-8064
8:39AM ET 10/07/2021 MT Newswires

Jounce Therapeutics (JNCE) has initiated patient enrollment in expansion cohorts of a phase 1 clinical trial of JTX-8064 monotherapy and combination...